Minimal Optimal Dose of Sugammadex in Elective Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-03

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Time of appearance of TOF Ratio \>0,9 with different doses of Sugammadex

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Different Reversal Agents in Pediatric Day-case Cancer Surgery

NCT03996655

Post-operative Residual Curarization

UNKNOWN PHASE4

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

NCT03513406

Burns

COMPLETED PHASE3

Sugammadex: Effect on the Awareness Monitoring and Hemodynamics

NCT01301261

Surgical Procedure, Unspecified

UNKNOWN NA

Sugammadex and Smoker's Neuromuscular Block

NCT05313100

Neuromuscular Blockade Smoking

COMPLETED PHASE4

"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"

NCT02375217

Anesthesia Recovery

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design: monocentric, prospective, controlled, randomized, double-blind study Inclusion criteria: women and men\> 18 years old, elective surgery, BMI \<30, patients giving consent to free and informed participation in writing;

Exclusion criteria:

* minor patients;
* Patients refusing to sign the consent;
* Patients included in another protocol within 3 months;
* Pregnant or lactating patients;
* Patients with a history of allergy to Sugammadex;
* Patients with known neuromuscular disease;
* Patients with renal or hepatic impairment.

Course of the study :

* 40 patients will be recruited at the time of the anesthesia consultation and randomized to double blind in 8 groups (the day before surgery)
* All patients will benefit from general anesthesia. Anesthetic management

(1- 3mg / kg / IV propofol, 0.2 μg / IV sufentanil, 0.6 mg / kg rocuronium and maintenance anesthesia with sevoflurane) will be standardized for all patients.
* Upon administration of rocuronium the acceleromyography transducer will be attached to the distal phalanx of the thumb, and repeated TOF stimulation will be applied to the ulnar nerve wrist at intervals of 15 seconds. Neuromuscular monitoring is continued until the end of the anesthesia.
* Once the first answer (1st twitch) appeared a dose of sugammadex will be administered according to the group whose patient was randomized: Test Groups Control Groups Group 1: Placebo + TOF 1 Group 1bis: Placebo + TOF2 Group 2: 0.5 mg / kg + TOF1 Group 2bis: 0.5 mg / kg + TOF2 Group 3: 1mg / kg + TOF1 Group 3bis: 1mg / kg + TOF2 Group 4: 2mg / kg + TOF 1 Group 4bis: 2mg / kg + TOF 2
* Then a standard dose of 4mg / kg will be administered at the end of the procedure before awakening to all patients who have signs of residual curarization (TOF ratio \<0.9). The pharmacy will be responsible for preparing the different doses of sugammadex, the syringe will be carefully covered and packaged, will contain an equal volume so that the anesthetists do not know which group the patient belongs to. Data collection: In real time during the intervention by the anesthesiologist in charge of patient Method of Analysis: Analysis of intent-to-treat data

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Time of a TOF Ratio >0,9

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel, Double blind Monocentric Prospective Vs placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

women and men\> 18 years of age Elective Surgery BMI \<30, patients who gave consent to free and informed participation in writing

Exclusion Criteria

* minor patients;
* patients refusing to sign consent;
* patients included in another protocol within 3 months;
* pregnant or nursing patients;
* patients with a history of allergy to Sugammadex;
* patients with known neuromuscular disease
* patients with renal or hepatic impairment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes